ClinConnect ClinConnect Logo
Search / Trial NCT06312241

Metacognitive Training-Silver BeWell in Older Adults

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Mar 6, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Metacognitive Training Intervention Older Adults Cognitive Behavioral Therapy Mct Silver

ClinConnect Summary

This clinical trial is studying a program called Metacognitive Training-Silver (MCT-Silver) BeWell, which aims to help older adults improve their mental well-being and reduce depressive symptoms. The trial is taking place in community settings, like social-psychiatric centers and nursing homes, and is looking at how well older adults accept and benefit from this training over a period of 10 weeks.

To participate, you need to be at least 60 years old, able to speak German, and willing to join the group sessions. It's important that you can hear and see well enough to take part, and you should have the social skills to engage in group activities. However, individuals with severe depression, thoughts of suicide, or significant cognitive issues, like dementia, are not eligible. If you join, you can expect to attend group sessions designed to enhance your mental skills and well-being, and even if you miss some sessions but complete questionnaires, your responses will still be included in the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Informed consent
  • Age 60 years or older
  • Sufficient command of the German language
  • Willingness to participate in intervention over a period of 10 weeks (participants who do not attend the intervention, but complete questionnaires will also be included in the analysis)
  • Visual and auditory acuity adequate for participation in group sessions
  • Ability to participate in the group setting (ability to participate in the group setting will be assessed during a screening interview (e.g., adequate social skills)).
  • Exclusion Criteria:
  • Acute suicidality as assessed by BDI-II Item 9
  • Dementia (MMSE \< 24) or evidence of severe organic brain dysfunction

About Universitätsklinikum Hamburg Eppendorf

Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.

Locations

Hamburg, , Germany

Patients applied

0 patients applied

Trial Officials

Brooke Viertel, PhD

Principal Investigator

Universitätsklinikum Hamburg-Eppendorf

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported